Skin treatments developer Syntopix has signed a second agreement with Sinclair Pharma.
This time Sinclair is paying a development contract fee to develop a combination of Sinclair’s Delmopinol and some potentially synergistic anti-microbial compounds in to proof of concept development formulations. Syntopix will receive royalties on any commercialised treatments.
The first agreement was announced in April and involved identifying anti-microbial compounds to augment Decapinol.
At 62p a share, Syntopix is valued at £6.64m.
© 2021 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.